Type 1 Diabetes
Clinical Trial

Baricitinib in new onset type 1 diabetes
(the BANDIT trial)

About the trial

Researchers at St Vincent’s Institute in Melbourne (SVI) have discovered that a drug called baricitinib may help people who have type 1 diabetes to produce insulin for longer after diagnosis. It is expected to stop the immune system from attacking the insulin-producing cells in the pancreas. There are no approved treatments that are able to do this.

Baricitinib is approved around the world for patients with rheumatoid arthritis. In a global first, the BANDIT trial will test baricitinib's effectiveness in people recently diagnosed with type 1 diabetes.

Watch the video


BANDIT trial participants must be aged 10 - 30 years old, and must have been diagnosed with type 1 diabetes within the past 100 days.

Study sites

The Australian-based trial is funded by JDRF, and will run at three sites in Melbourne: The Royal Melbourne Hospital, The Royal Children’s Hospital and St Vincent’s Hospital Melbourne and at one site in Adelaide - the Women's and Children's Hospital.

Participants do not have to already be patients of these hospitals, and they would be expected to continue to see their usual doctor during and after the trial when necessary.

How it works

Participants will be assigned by chance to either a group that receives baricitinib or a group that receives an inactive substance called a placebo. Two thirds of the trial participants will receive baricitinib and one third will receive the placebo. The trial will last for two years. In the first year, participants will take baricitinib or placebo tablets orally once per day. They will be required to visit the trial site 12 times during the first year. In the second year, participants return twice for tests and monitoring.

Why should I participate?

By participating in this trial, you will be advancing type 1 diabetes research and will potentially help thousands of future type 1 diabetes patients – children and adults.

Participants may also benefit from the additional monitoring of their diabetes provided by the trial and from close interaction with the research team.